contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


clinics-in-the-us-can-now-purchase-tinearity-g1-through-a-national-trading-platform

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Duearity

Duearity Americas Inc has entered into a partnership with a national distributor in the USA that has a unique digital trading platform for products in the field of hearing health. The distributor...

<div class="mfn-preamble"><p><strong>Duearity Americas Inc has entered into a partnership with a national distributor in the USA that has a unique digital trading platform for products in the field of hearing health. The distributor has evaluated Tinearity G1 and is now offering Tinearity G1 to clinics throughout the United States.</strong></p></div><div class="mfn-body"><p>The distribution company Oaktree Products has evaluated Tinearity G1 and has decided that the product should be included in the company's trading platform, which means that the product can be sold and distributed to clinics throughout the United States. The advantage for Duearity is, firstly, that the distributor is licensed in all states. Secondly, the distributor has high trust among clinics, which puts a stamp of quality on Duearity as a company and Tinearity G1 as a product. Thirdly, the collaboration means that clinics can easily order Tinearity G1 on Oaktree's trading platform. As a consequence, this means a simplified distribution chain where the product is sent directly to clinics via Oaktree. Oaktree Products only sells products in the field of ear and hearing health and only to professionals and clinics.</p><p>Duearity Americas Inc are involved in negotiations with more distributors in the US. The goal is to enter into a second distributor agreement during the first quarter of 2024 with a company that has a well-developed sales organization in the US and that covers important sales channels in the country.</p></div><div class="mfn-footer mfn-contacts mfn-365b0c3c64d7"><p><strong class="mfn-heading-1">For more information, please contact</strong></p><hr><p>Fredrik Westman, CEO<br>+46 738 - 145 215<br>fredrik.westman@duearity.com&nbsp;<br>www.duearity.com</p></div><div class="mfn-footer mfn-about mfn-57c6e976a4c7"><p><strong class="mfn-heading-1">About Duearity AB (publ)</strong></p><hr><p>Duearity is a medtech company that develops and produces solutions aiming to relieve tinnitus symptoms and make everyday life easier for those who suffer from tinnitus. The company will offer the products Tinearity and Tinearity-AI.</p><p>Tinearity G1 is CE marked, has 510(k) clearance and is sold in the EU and in the US.</p><p>Tinearity transmits white noise using non-invasive Bone Conduction Technology to the inner ear in order to relieve symptoms. Tinearity AI will use artificial intelligence to help people anticipate the symptoms and relieve their discomfort.</p><p>The company is listed on Nasdaq First North. The company's headquarters are located in Malmö, Sweden.<br>Certified Adviser is Svensk Kapitalmarknadsgranskning AB (SKMG), <a rel="noopener" href="http://www.skmg.se/">www.skmg.se</a>.<br>www.duearity.com.<br></p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/c814f3d0-93e0-449c-a88d-1f5ced3c313d/clinics-in-the-us-can-now-purchase-tinearity-g1-through-a-national-trading-platform.pdf" class="mfn-generated mfn-primary">Clinics in the US can now purchase Tinearity G1 through a national trading platform</a></p></div>

Clinics in the US can now purchase Tinearity G1 through a national trading platform